New York State Common Retirement Fund Grows Position in ImmunityBio, Inc. (NASDAQ:IBRX)

New York State Common Retirement Fund raised its holdings in shares of ImmunityBio, Inc. (NASDAQ:IBRX) by 62.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 32,418 shares of the company’s stock after purchasing an additional 12,500 shares during the quarter. New York State Common Retirement Fund’s holdings in ImmunityBio were worth $83,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in IBRX. State Street Corp lifted its holdings in ImmunityBio by 10.1% during the third quarter. State Street Corp now owns 8,654,460 shares of the company’s stock valued at $32,195,000 after purchasing an additional 790,408 shares during the last quarter. Barclays PLC increased its position in shares of ImmunityBio by 127.4% during the third quarter. Barclays PLC now owns 361,036 shares of the company’s stock valued at $1,344,000 after buying an additional 202,248 shares during the period. GSA Capital Partners LLP increased its position in shares of ImmunityBio by 290.3% during the third quarter. GSA Capital Partners LLP now owns 107,985 shares of the company’s stock valued at $402,000 after buying an additional 80,318 shares during the period. XTX Topco Ltd increased its position in shares of ImmunityBio by 309.4% in the third quarter. XTX Topco Ltd now owns 92,910 shares of the company’s stock worth $346,000 after purchasing an additional 70,215 shares during the last quarter. Finally, Advantage Alpha Capital Partners LP bought a new position in shares of ImmunityBio in the third quarter worth approximately $257,000. 8.58% of the stock is owned by hedge funds and other institutional investors.

ImmunityBio Price Performance

Shares of NASDAQ IBRX opened at $3.06 on Thursday. ImmunityBio, Inc. has a one year low of $2.28 and a one year high of $10.53. The stock has a market capitalization of $2.13 billion, a P/E ratio of -3.33 and a beta of 0.94. The firm’s 50 day simple moving average is $3.04 and its two-hundred day simple moving average is $3.72.

ImmunityBio (NASDAQ:IBRX) last issued its earnings results on Monday, March 3rd. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.11. The firm had revenue of $7.55 million during the quarter, compared to the consensus estimate of $8.74 million. As a group, equities analysts expect that ImmunityBio, Inc. will post -0.92 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on IBRX. D. Boral Capital restated a “buy” rating and issued a $30.00 price objective on shares of ImmunityBio in a research report on Friday, February 28th. BTIG Research initiated coverage on shares of ImmunityBio in a research report on Friday, January 10th. They set a “buy” rating and a $6.00 price target on the stock.

ImmunityBio Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.